Fly News Breaks for March 13, 2015
OMED
Mar 13, 2015 | 05:52 EDT
Following the company's Q4 results, Piper Jaffray says it views OncoMed's clinical pipeline as "dramatically" undervalued. Piper notes the company ended 2014 with $232M in cash and guided to end 2015 with greater than $120M. It reiterates an Overweight rating on the stock with a $43 price target.
News For OMED From the Last 2 Days
There are no results for your query OMED